Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405574 | 0.98 | HDAC1 (0.52) | HDAC1HDAC2PPARALTA4HLTB4R | |
| SCHEMBL1270026 | 0.97 | HDAC1 (0.51) | HDAC1HDAC2PPARALTA4HLTB4R | |
| SCHEMBL1269120 | 0.93 | APP (0.61) | HDAC1HDAC2FFAR4APP | |
| SCHEMBL1270374 | 0.91 | CYP3A4 (0.58) | LTA4HLTB4RRXRATSHR | |
| SCHEMBL1268950 | 0.91 | LTA4H (0.47) | HDAC1HDAC2PPARALTA4HLTB4R | |
| SCHEMBL1270236 | 0.91 | HDAC1 (0.46) | HDAC1HDAC2PPARALTA4HLTB4R | |
| SCHEMBL1270074 | 0.90 | HDAC1 (0.55) | HDAC1HDAC2LTA4HAPP | |
| SCHEMBL1270202 | 0.89 | HDAC1 (0.44) | HDAC1HDAC2PPARALTA4HLTB4R | |
| SCHEMBL1269393 | 0.88 | HDAC1 (0.53) | HDAC1HDAC2LTA4HAPP | |
| SCHEMBL1269389 | 0.87 | HDAC1 (0.52) | HDAC1HDAC2LTA4HAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879907-B2 | Peroxisome Proliferator-Activated Receptor (PPAR) activators such as 3-{4-[3-(4-benzyloxy-3-methoxyphenyl)propyl]-3-butoxyphenyl}propanoic acid, used in dermatology, cosmetics, cardiovascular diseases, immunology and/or lipid metabolism | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-02-01 | — | — | US | claimed |
| EP-2155662-B1 | NOVEL DERIVATIVES OF 3-PHENYL PROPANOIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-12-01 | — | — | EP | claimed |
| US-20100158843-A1 | NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-24 | — | — | US | claimed |
| US-7879907-B2 | Peroxisome Proliferator-Activated Receptor (PPAR) activators such as 3-{4-[3-(4-benzyloxy-3-methoxyphenyl)propyl]-3-butoxyphenyl}propanoic acid, used in dermatology, cosmetics, cardiovascular diseases, immunology and/or lipid metabolism | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-02-01 | — | — | US | disclosed |
| EP-2155662-B1 | NOVEL DERIVATIVES OF 3-PHENYL PROPANOIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100158843-A1 | NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-24 | — | — | US | disclosed |
| EP-2155662-A2 | NOVEL DERIVATIVES OF 3-PHENYL PROPANOIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008152333-A9 | NOVEL DERIVATIVES OF 3-PHENYL PROPANOIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-10 | — | — | WO | disclosed |
| WO-2008152333-A2 | NOVEL DERIVATIVES OF 3-PHENYL PROPANOIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158843-A1 | NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | HDAC1 520/4885HDAC2 455/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.